CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Sandhill Therapeutics
Main focus: Gene editing for next generation cellular therapies
Company stage: Pre-clinical
Diseases: Haematological- and solid tumours
Genome editing tool: CRISPR-Cas9 (Through Editas Medicine)
Funding stage: Private
Location: Dallas, Texas, USA
Website: https://www.sandhilltx.com/
Partners: Editas Medicine
Sandhill’s proprietary technology, called BINATE™, leverages dual innate cell synergy, resulting in a highly activated, readily available, universal off-the-shelf treatment for both solid tumours and blood cancers. Through its collaboration with Editas Medicine, the company is developing next generation CRISPR-edited cellular therapies.
